Amendments to the Claims:

This listing of the claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

- 1. (Currently Amended) Metal complex of the general formula $M(L)_n$, wherein \underline{M} is metal selected from the transition metals, each L is independently selected and represents a ligand, and at least one L is vitamin B_{12} (cyanocobalamin) or a derivative thereof which is bound through the nitrogen atom of its cyanide group to M, which is an element selected from the transition metals, thus, forming a M-NC-[Co] moiety, wherein [Co] represents vitamin B_{12} or its derivative without cyanide, and wherein n is 1, 2, 3, 4, 5 or 6.
- 2. (Currently Amended) Metal complex as claimed in claim 1, wherein the transition metal M is selected from technetium, ruthenium, rhodium, rhenium, palladium, platinum, iridium and or copper.
- 3. (Currently Amended) Metal complex as claimed in claim 1-or 2, wherein the metal M is a radioisotope of the elements Re or Tc, such rhenium or technetium as 99m Tc, 188 Re, 186 Re.
- 4. (Currently Amended) Metal complex as claimed in any one of the claims 1-1, wherein when M is technetium or rhenium, the other ligandsn is 4, 5 or 6, and three occurrences of L are comprise three-carbonyl groups (CO's) and optionally a bidentate ligand, optionally coupled to another metal complex or other molecule, such as a biologically active molecule or fluorescing agent.
- 5. (Currently Amended) Metal complex as claimed in claim 4<u>18</u>, wherein the bidentate ligand is selected from comprises two aliphatic and/or aromatic amine parts, two aliphatic or aromatic amine parts, or one aliphatic or aromatic amine part and an anionic group-such as a carboxylate, a thiolate or a hydroxylate.
- 6. (Currently Amended) Metal complex as claimed in claim $5\underline{18}$, wherein the bidentate ligand is selected from α -amino acids or derivatives of picolinic acid.
- 7. (Currently Amended) Metal complex as claimed in any one of the claims 1-3, wherein when M is platinum, and L is independently selected from ligands containing N, S, P, O, C as the metal binding atom or any other donor with one non-binding electron pair available for coordination to the metal, optionally coupled to another metal complex or another molecule,

such as a biologically active molecule or a fluorescing molecule.

- 8. (Currently Amended) Metal complex as claimed in any one of the claims 4 or 7, wherein an occurrence of L is a bidentate ligand coupled to a the other molecule is selected from the group consisting of fluorescing agents, pharmacophores with cytotoxic, cytostatic or other pharmacological activities, optical dyes, NIR dyes, or phosphorescent dyes, and pharmacophores.
- 9. (Currently Amended) Metal complex as claimed in claim 8, wherein the <u>bidentate ligand is coupled to a fluorescing</u> agent is selected from <u>the group consisting of fluoresceine</u>, pyrene, acridine, <u>and dansyl</u>.
- 10. (Currently Amended) Metal complex as claimed in claim 8, wherein the <u>bidentate ligand is</u> coupled to a pharmacophores selected from the group consisting of cytotoxic agent is tamoxifen, methotrexate or and cyclophosphamid.
- 11. (Cancelled).
- 12. (Currently Amended) Process for preparing a metal complex as claimed in any one of the claims 1-11, comprising:
- mixing ef-vitamin B_{12} or a derivative thereof with a precursor complex of the general formula $M(L)_{n-1}L'$, wherein M is a transition metal, n is 2, 3, 4, 5 or 6, L' is a ligand to be substituted by the vitamin B_{12} or the derivative thereof, and each L is independently selected and is a ligand, to obtain a metal complex with a stable [Co]-CN-M bridge.
- 13. (Currently Amended) Precursor complex for use in the preparation of metal complex of claim 1 and having the general formula $M(L)_{n-1}L'$, wherein M is a transition metal, n is 2, 3, 4, 5 or 6, L' is a ligand to be substituted, and each L is independently selected and is a ligand for use in the preparation of metal complexes as claimed in any one of the claims 1-11.
- 14. (Cancelled).
- 15. (Currently Amended) Metal-Use of a metal complex as claimed in any one-of the claims 1-11, for use in radiodiagnostics, chemotherapy or radionuclide therapy.
- 16. (Currently Amended) Metal complex as claimed in any one of the claims 1-11, wherein M is a catalytically active metal for use in catalysis.

- 17. (New) Metal complex as claimed in claim 3, wherein M is ^{99m}Tc, ¹⁸⁸Re, or ¹⁸⁶Re.
- 18. (New) Metal complex as claimed in claim 4, wherein an occurrence of L is a bidentate ligand.
- 19. (New) Metal complex as clamed in claim 4, wherein an occurrence of L is a bidentate ligand coupled to a metal complex, a biologically active molecule or a fluorescing agent.
- 20. (New) Metal complex as claimed in claim 5, wherein the bidentate ligand comprises one aliphatic or aromatic amine part and an anionic group, wherein the anionic group is a carboxylate, a thiolate or a hydroxylate.
- 21. (New) Metal complex as claimed in claim 1, wherein M is platinum, L is independently selected from:

ligands containing N, S, P, O, C as the metal binding atom or any other donor with one non-binding electron pair available for coordination to the metal; and

ligands containing N, S, P, O, C as the metal binding atom or any other donor with one non-binding electron pair available for coordination to the metal coupled to another metal complex, a biologically active molecule, or a fluorescing molecule.

22. (New) Metal complex as claimed in claim 1 having a structural formula selected from the group consisting of:

23. (New) Precursor complex as claimed in claim 13 having a structural formula selected from the group consisting of: